Press Releases
Date picker
Category
Results per page
Kancera announces intention to change company name to Novakand Pharma
Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company’s strategic decision to focus on cardiovascular diseases.
Kancera signs letter of intent agreement with Recardio for licensing of KAND567 and KAND145
Regulatory
Kancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145Recardio’s phase III ready dutogliptin…
Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the fourth quarter 2024Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 8,5 million (SEK 17,1 million).Operating…
Interim Report Third Quarter 2024, July 1 – September 30 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the third quarter 2024Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 10,2 million (SEK 9,2 million).Operating…
Kancera focuses on cardiovascular diseases
Development resources are focused on cardiovascular diseases, initially with focus on treatment of STEMI based on the positive phase IIa results in the FRACTAL-study.Extensive market access research concerning the preliminary…
Kancera appoints Robert Edfors as Chief Medical Officer
Kancera AB (publ) today announces that Robert Edfors is appointed as Chief Medical Officer (CMO) at Kancera, effective on November 1, 2024. Robert Edfors, specialist in cardiology and internal medicine,…
Kancera gives an operational update concerning its clinical development program
In connection with the interim report for the second quarter 2024, Kancera AB (publ) today provides a general operational update concerning its clinical development program and reports that:the phase IIa…
Interim Report Second Quarter 2024, April 1 – June 30, Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the second quarter 2024Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 9,7 million (SEK 16,5 million).Operating…
Kancera’s FRACTAL study results to be presented at the ESC 2024 Conference
Kancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.
Phase Ib completed and the recommended phase II dose is set in the ongoing KANDOVA study
Kancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567…